JemperliActive Ingredient(s): Dostarlimab-gxly
FDA Approved: * April 22, 2021
Pharm Company: * GLAXOSMITHKLINE
Dostarlimab, sold under the brand name Jemperli, is a monoclonal antibody used as a medication for the treatment of endometrial cancer. The most common side effects reported in the US include fatigue/asthenia, nausea, diarrhea, anemia, and constipation. Additional common side effects reported in the EU include vomiting, joint pain, itching, rash, fever, and hypothyroidism (low lev... [wikipedia]* May have multiple approval dates, manufacturers, or labelers.